Analyst Ratings
Upgrades, downgrades, and price-target changes from Wall Street firms.
BTIG Reiterates Buy Rating for Gain Therapeutics, Inc. (GANX)
BTIG maintains its buy rating on Gain Therapeutics, Inc. with a $5 price target.
UBS Reiterates Buy Rating on Kinross Gold with $30 Price Target
UBS analyst Daniel Major maintains a buy rating on Kinross Gold with a $30 target.
UBS Reiterates Buy Rating for SSRM, Sets $40 Price Target
UBS analyst George Eadie maintains a buy rating on SSRM with a target price of $40.
Tigress Financial Reiterates Buy Rating for Carnival Corp
Tigress Financial keeps its buy rating on Carnival with a $42 target.
BTIG Reiterates Buy Rating on GANX with $5 Price Target
BTIG maintains its optimistic stance on GANX, reaffirming a Buy rating and setting a $5 price target.
Needham Reiterates Buy Rating on Taysha Gene Therapies
Needham maintains its buy rating for Taysha Gene Therapies with a $12 price target.
Jefferies Upgrades ABIVAX Rating to Buy with $158 Target
Jefferies analyst raises ABIVAX to Buy, setting a new price target of $158.
D. Boral Capital Raises Price Target on Anixa Biosciences to $10
Anixa Biosciences receives a new 'buy' rating and a $10 price target from D. Boral Capital.
Citigroup Reiterates Buy Rating on California Resources
Citigroup maintains a bullish outlook on California Resources with a $70 price target.
BTIG Reiterates Buy Rating on Strategy Inc (MSTR) with $250 Target
BTIG maintains its buy rating on Strategy Inc with a $250 price target.
BTIG Reiterates Buy Rating for Palo Alto Networks
BTIG has reaffirmed its buy rating on Palo Alto Networks, setting a price target of $380.
UBS Reiterates Buy Rating on Franco-Nevada
UBS maintains a buy rating on Franco-Nevada with a $280 price target.
UBS Reiterates Buy Rating for Warrior Met Coal
UBS maintains its buy rating for Warrior Met Coal with a $100 price target.
UBS Reiterates Buy Rating for Alcoa with $68 Price Target
UBS maintains its optimistic outlook on Alcoa, setting a $68 price target.
UBS Reiterates Buy Rating on CNR with $100 Target
UBS maintains its buy rating for CNR, aiming for a $100 price target.
UBS Reiterates Buy Rating for Royal Gold, Inc. (RGLD)
UBS maintains its buy rating on Royal Gold, Inc. with a $280 price target.
UBS Reiterates Buy Rating on Wheaton Precious Metals
UBS analyst Daniel Major maintained a buy rating on Wheaton Precious Metals Corp., targeting $150.
UBS Reiterates Buy Rating on Newmont Corporation
UBS analyst Daniel Major maintains a buy rating on Newmont Corporation with a price target of $120.
CIBC Reiterates Buy Rating on TFI International with $172 Target
TFI International received a buy rating reiteration from CIBC with a price target of $172.
Maxim Group Reiterates Buy Rating on PMNT
Maxim Group reaffirms its buy rating for PMNT with a target price of $0.40.
Citigroup Reiterates Sell Rating on Cullen/Frost Bankers
Citigroup maintains a sell rating on Cullen/Frost Bankers with a $145 price target.
Citigroup Reiterates Buy Rating on PNC Financial Services
Citigroup maintains its buy rating on PNC Financial with a $280 price target.
Citigroup Reiterates Buy Rating on H.B. Fuller Company
Citigroup maintains its buy rating on H.B. Fuller with a $75 target.
Citigroup Reiterates Buy Rating on Immunovant, Inc. (IMVT)
Citigroup maintains its buy rating on Immunovant with a $61 price target.